Qpex Biopharma is developing a pipeline of agents addressing critical needs for the treatment of infectious diseases in the inpatient and outpatient settings. Qpex management has a record of deep expertise in the discovery, development and regulatory approval of anti-infective medicines, including an extensive record of working with public/private partnerships focused on new antibiotics to combat antimicrobial resistance.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/22/18 | $33,000,000 | Series A |
Adams Street Partners Hatteras Venture Partners LYZZ Capital New Enterprise Associates  Stanford University | undisclosed |
